Axogen, Inc. to Participate at Upcoming Investor Conferences
May 23 2019 - 7:00AM
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and
marketing innovative surgical solutions for damage or transection
to peripheral nerves, today announced that members of its
management team will participate in three upcoming investor
conferences during June.
Karen Zaderej, chairman, CEO, and president will
present at the Jefferies 2019 Healthcare Conference in New York
City. The presentation is scheduled for Wednesday, June 5, 2019 at
3:00 p.m. ET.
Peter J. Mariani, chief financial officer, will present at the
William Blair 39th Annual Growth Stock Conference in Chicago. The
presentation is scheduled for Thursday, June 6, 2019 at 9:20 a.m.
CST (10:20 a.m. ET).
Mr. Mariani will also present at the JMP Securities Life
Sciences Conference in New York City. The presentation is scheduled
for Wednesday, June 19, 2019 at 9:00 a.m. ET.
The presentations will be webcast live and
accessible through the Investors page at www.axogeninc.com. For
those not available to listen to the live broadcast, a replay will
be archived for 90 days and available through the Investors page on
www.axogeninc.com.
About AxogenAxogen (AXGN) is the leading
company focused specifically on the science, development and
commercialization of technologies for peripheral nerve regeneration
and repair. We are passionate about helping to restore peripheral
nerve function and quality of life to patients with physical damage
or transection to peripheral nerves by providing innovative,
clinically proven and economically effective repair solutions for
surgeons and health care providers. Peripheral nerves provide the
pathways for both motor and sensory signals throughout the body.
Every day, people suffer traumatic injuries or undergo surgical
procedures that impact the function of their peripheral
nerves. Physical damage to a peripheral nerve, or the
inability to properly reconnect peripheral nerves, can result in
the loss of muscle or organ function, the loss of sensory feeling,
or the initiation of pain.
Axogen's platform for peripheral nerve repair features a
comprehensive portfolio of products, including Avance® Nerve Graft,
a biologically active off-the-shelf processed human nerve allograft
for bridging severed peripheral nerves without the comorbidities
associated with a second surgical site; Axoguard® Nerve Connector,
a porcine submucosa extracellular matrix (ECM) coaptation aid for
tensionless repair of severed peripheral nerves; Axoguard® Nerve
Protector, a porcine submucosa ECM product used to wrap and protect
damaged peripheral nerves and reinforce the nerve reconstruction
while preventing soft tissue attachments; and Avive® Soft
Tissue Membrane, a minimally processed human umbilical cord
membrane that may be used as a resorbable soft tissue covering to
separate tissue layers and modulate inflammation in the surgical
bed. Along with these core surgical products, Axogen also offers
Acroval® Neurosensory & Motor Testing System and Axotouch®
Two-Point Discriminator. These evaluation and measurement tools
assist health care professionals in detecting changes in sensation,
assessing return of sensory, grip, and pinch function, evaluating
effective treatment interventions, and providing feedback to
patients on peripheral nerve function. The Axogen portfolio of
products is available in the United States, Canada, the United
Kingdom, and several other European and international
countries.
Cautionary Statements Concerning Forward-Looking
Statements This press release contains “forward-looking”
statements as defined in the Private Securities Litigation Reform
Act of 1995. These statements are based on management's current
expectations or predictions of future conditions, events, or
results based on various assumptions and management's estimates of
trends and economic factors in the markets in which we are active,
as well as our business plans. Words such as “expects,”
“anticipates,” “intends,” “plans,” “believes,” “seeks,”
“estimates,” “projects,” “forecasts,” “continue,” “may,” “should,”
“will,” “goals,” and variations of such words and similar
expressions are intended to identify such forward-looking
statements. The forward-looking statements may include, without
limitation, our 2019 guidance, statements regarding our assessment
of our internal controls over financial reporting, our growth,
product development, product potential, financial performance,
sales growth, product adoption, market awareness of our products,
data validation, our visibility at and sponsorship of conferences
and educational events. The forward-looking statements are and will
be subject to risks and uncertainties, which may cause actual
results to differ materially from those expressed or implied in
such forward-looking statements. Forward-looking statements
contained in this press release should be evaluated together with
the many uncertainties that affect our business and our market,
particularly those discussed under Part I, Item 1A., “Risk
Factors,” of our Annual Report on Form 10-K for the fiscal year
ended December 31, 2018, as well as other risks and cautionary
statements set forth in our filings with the U.S. Securities and
Exchange Commission. Forward-looking statements are not a guarantee
of future performance, and actual results may differ materially
from those projected. The forward-looking statements are
representative only as of the date they are made and, except as
required by applicable law, we assume no responsibility to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events, changed circumstances, or
otherwise.
Contact:Axogen, Inc.Kaila
Krum, Vice President, Investor Relations and Corporate
Developmentkkrum@axogeninc.comInvestorRelations@axogeninc.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Sep 2023 to Sep 2024